Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

Dr. Michael Lazar

Minimally Invasive Prostate Cancer Treatment HIFU Now Available in the U.S.

sonablate500After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation.

HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around the country. Dr. Lazar has been treating patients with HIFU since 2007 and is one of only three U.S. physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

John W. Linn, chief executive officer of HPS commented, “I have known Dr. Lazar since 2007 and have been impressed with his patient care and dedication to the HIFU technology since his first treatment. He is the ideal medical director for HPS and for teaching this new technology to US physicians.”

Lazar will also operate his own HIFU Program in partnership with HPS, offering prostate treatments in downtown San Francisco near Union Square at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport for patients interested in traveling from around the country for HIFU treatments. The actual Sonablate device has just been delivered to the Surgery Center in San Francisco, marking the first time ever that a HIFU device will be available at a medical center in the United States.

“It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users. Over the years, physicians in various stages of training have shown remarkable enthusiasm for providing HIFU for their prostate cancer patients, but they did not see a clear path for obtaining accessibility to the technology after FDA approval,” said Lazar. “HIFU Prostate Services takes the mystery and tedium out of the process by providing the highest quality of care, support and technology to the patient and to the urology community. Men who choose HIFU can contact HPS and then be referred to a regional HIFU surgeon. This approach facilitates wide availability of this treatment option for American men.”

HIFU offers patients a single, outpatient treatment for prostate cancer that is bloodless and allows men to return to their normal lifestyles within a few days. Although HIFU is designed as a single treatment, it can be repeated if needed. HIFU may also be used to treat patients that have failed radiation therapy and it does not preclude any future treatments including surgery or radiation.

About HIFU Prostate Services, LLC & Dr. Michael Lazar

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, N.C.

lazar close up

Dr. Michael Lazar

Dr. Michael Lazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, California since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For additional information, visit Dr. Michael Lazar at www.californiahifu.com, 707-546-5553 or www.hifuprostateservices.com. Media Contact: John Linn, 704-737-5925
.

HIFU Prostate Services Names Michael J. Lazar, MD Medical Director

Nov. 4, 2015 — HIFU Prostate Services (HPS) has named Dr. Michael Lazar as HPS Medical Director. As HPS Medical Director Dr. Lazar will provide medical guidance and proctoring to new physicians that are being trained on the Sonablate® HIFU system in surgery centers around the country. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence, which are typically reported with surgery and radiation. Lazar has been treating with HIFU since 2007 and is one of three US physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

Dr. Lazar will operate his own HIFU Program, in partnership with HPS, offering prostate treatments in downtown San Francisco, near Union Square, at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment.

By | November 11th, 2015|Dr. Michael Lazar, HIFU, News|0 Comments

HIFU Now Available In the U.S. Ending a Long Awaited FDA Approval Process

sonablate500After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation.

HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around the country. Dr. Lazar has been treating patients with HIFU since 2007 and is one of only three U.S. physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

John W. Linn, chief executive officer of HPS commented, “I have known Dr. Lazar since 2007 and have been impressed with his patient care and dedication to the HIFU technology since his first treatment. He is the ideal medical director for HPS and for teaching this new technology to US physicians.”

Dr. Lazar will also operate his own HIFU Program in partnership with HPS, offering prostate treatments in downtown San Francisco near Union Square at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport for patients interested in traveling from around the country for HIFU treatments. The actual Sonablate device has just been delivered to the Surgery Center in San Francisco, marking the first time ever that a HIFU device will be available at a medical center in the United States.

“It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users. Over the years, physicians in various stages of training have shown remarkable enthusiasm for providing HIFU for their prostate cancer patients, but they did not see a clear path for obtaining accessibility to the technology after FDA approval,” said Lazar. “HIFU Prostate Services takes the mystery and tedium out of the process by providing the highest quality of care, support and technology to the patient and to the urology community. Men who choose HIFU can contact HPS and then be referred to a regional HIFU surgeon. This approach facilitates wide availability of this treatment option for American men.”

HIFU offers patients a single, outpatient treatment for prostate cancer that is bloodless and allows men to return to their normal lifestyles within a few days. Although HIFU is designed as a single treatment, it can be repeated if needed. HIFU may also be used to treat patients that have failed radiation therapy and it does not preclude any future treatments including surgery or radiation.

About HIFU Prostate Services, LLC & Dr. Michael Lazar

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, N.C.

lazar close upLazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, California since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For additional information, visit Dr. Michael Lazar at www.californiahifu.com, 707-546-5553 or www.hifuprostateservices.com. Media Contact: John Linn, 704-737-5925

By | November 10th, 2015|Dr. Michael Lazar, HIFU, Prostate Cancer|0 Comments

North Bay Business Journal article on Dr. Michael Lazar — HIFU: poised for approval by FDA

Click to view full story from North Bay Business Journal …. A nonsurgical, outpatient treatment for prostate cancer, with a low rate of side effects, is poised for approval by the U.S. Food and Drug Administration within the next few weeks.  Treatment with high-intensity focused ultrasound (HIFU) waves use heat focused at a specific location to destroy the area of the prostate gland affected with cancer, while any tissue outside of the focal point remains unharmed.  “The oncological results for HIFU are broadly comparable to radical surgery or radiation but the side effects are less,” said Dr. Michael Lazar, a urology specialist in Santa Rosa.  HIFU is most effective for patients with early stage prostate cancer where the cancer is localized to the prostate. The procedure preserves healthy tissue and preserving nerves, urine flow and erectile function in about 80 percent of cases compared to 40 percent–50 percent with surgery or radiation.  HIFU is also performed on an out-patient basis, taking one to four hours. A urinary catheter is inserted after the procedure and must be kept in place for one to three weeks. The most common side effects are infections in the prostate area, and incontinence, to a lesser degree than other therapies.  Click to view full story from North Bay Business Journal ….

High Intensity Focused Ultrasound (HIFU) Therapy is Gaining International Acceptance for the Treatment of Medical Conditions

your-questions-answeredA growing number of international medical organizations have already adopted High Intensity Focused Ultrasound (HIFU) therapy for treating an increasing number of conditions, and as a viable option to traditional invasive surgery, according to Dr. Michael Lazar, a Santa Rosa, California-based Urologist and a leading advocate for HIFU as an effective treatment for prostate cancer.

Dr. Lazar states, “The scientific community has known for years that high heat kills cancer. But only in recent years has the science advanced to the point where focused ultrasound energy can be used to provide pinpoint accuracy, sparing healthy tissue and preserving nerves, urine flow and erectile function in a majority of cases compared with traditional procedures, while also delivering the required amount of heat needed to destroy, or ablate, cancer.”

Today HIFU is being deployed around the world, especially in Europe, for the treatment of abdominal kidney tumors, urological cancers, uterine fibroids, and to relieve neuropathic pain associated with bone cancer, in addition to being a non-invasive treatment for prostate cancer. Medical literature also reports the use of HIFU in treating liver, breast and brain tumors as well as other conditions.”

For example, according to the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) located in Vienna, Austria, positive results were achieved with transcranial Magnetic Resonance MR-guided focused ultrasound surgery (tcMRgFUS) as a non-invasive treatment of essential tremors, neuropathic pain and Parkinson’s disease. CIRSE also reports that there have also been some investigations into the use of HIFU for temporarily opening the blood-brain barrier, allowing absorption of drugs into the brain.

Furthermore, a minimally invasive catheter-based HIFU system — designed to ablate heart tissue responsible for atrial fibrillation — has been approved for use in Europe and is undergoing an FDA approved trial in the United States.

“Adoption of HIFU has proceeded at a faster rate among international medical communities than in the United States, however, there are hopeful signs that this technique will soon be available to a broader range of patients here at home so they will not have to travel to hospitals outside of the U.S. to take advantage of this procedure,” Dr. Lazar said.

For more information about Dr. Michael Lazar, go to the HIFU website or call (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, in Santa Rosa, CA 95405.

Indianapolis, Indiana-based SonaCare Medical LLC, a leading developer of minimally-invasive HIFU technology, is bringing several HIFU systems to market to meet growing global demand. SonaCare Medical, LLC, serves customers around the world through its family of affiliate companies including: USHIFU, International HIFU and Focus Surgery. For additional information, go to: www.sonacaremedical.com.

September is Prostate Cancer Awareness Month

Get a Checkup, Have a PSA Blood Test and Learn About Symptoms of the Disease as well as Treatment Options

Prostate cancer is the second leading cause of death following lung cancer, and about one man in 38 will die of the disease. However, statistics show that most men diagnosed with the prostate cancer do not die from it, and more than 2.9 million men in the U.S. who were found to have this cancer are alive today. But why take a chance? A simple screening involving an annual blood test to measure PSA levels gives doctors a way to assess the presence and pace of the disease and the need for ongoing monitoring, a biopsy or direct intervention.September is national Prostate Cancer Awareness Month. About 220,800 new cases of this type of cancer are reported each year, along with 27,540 deaths attributed to the disease annually. One in seven men will be diagnosed with prostate cancer during their lifetime. While only one man in 10,000 will typically get prostate cancer under age 40, the risk increases to six of every 10 men by age 65, according to the American Cancer Society.

Prostate cancer is the second leading cause of death following lung cancer, and about one man in 38 will die of the disease. However, statistics show that most men diagnosed with the prostate cancer do not die from it, and more than 2.9 million men in the U.S. who were found to have this cancer are alive today. But why take a chance? A simple screening involving an annual blood test to measure PSA levels gives doctors a way to assess the presence and pace of the disease and the need for ongoing monitoring, a biopsy or direct intervention.

“Why is there such a difference between cancers? Some prostate cancer is very aggressive and progresses quickly, while other forms take many years to become life threatening,” said Michael Lazar, a noted urologist with a practice in Santa Rosa, California and a leading proponent of non-invasive High Intensity Focused Ultrasound (HIFU) therapy for prostate cancer treatment.

You have a number of options if it is determined that you have this disease. These include traditional surgery to remove the prostate gland, radiation (including inserting irradiated pellets into the prostate), cryotherapy (freezing of the prostate), or non-invasive HIFU therapy using sound waves to pinpoint cancer cells and destroy them without damage to surrounding healthy tissue and minimal blood loss.

Side effects associated with invasive surgical procedures including a hospital stay, a longer recovery period plus scaring, adhesions and blood loss. There is also the risk of incontinence, erectile dysfunction (ED) and a decline of libido. Radiation can ionize otherwise healthy cells that can turn into cancer latter in life. With cryotherapy, side effects include 90% to 100% ED and urethral tissue scaring that can obstruct voiding. The HIFU procedure is virtually painless, takes only a few hours, and there are fewer side effects, thereby maintaining the quality of life. Most patients are up and around the same day.

In most instances, there are no significant symptoms during the early stages of prostate cancer, and symptoms may vary from one man to another, or can be caused by other conditions. However, there are some urinary symptoms that could signal cancer including: pain or a burning sensation while urinating as well as difficulty in starting or stopping, frequent urges to go during the night, an uncontrollable bladder, a decreased flow of the urine stream, or blood in the urine. Other symptoms include painful ejaculation or difficulty in getting an erection, swelling in the legs or pelvic area, pain or numbness in the feet, legs or hips, constant bone pain leading to fractures and blood in the semen.

“My advice to every man is to obtain a baseline PSA after age 40, then yearly exams and PSA tests after 50 years of age. For those having to make a treatment choice for prostate cancer, consider all options including HIFU. While not currently available in the U.S., HIFU is pending FDA approval and is available internationally at a full-service hospital in Puerto Vallarta, Mexico, where dozens of successful HIFU procedures have been performed by me and my highly trained team,” Dr. Lazar said.

For additional information, go to the website at www.californiahifu.com, or contact Dr. Michael Lazar’s office at (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, Santa Rosa, CA 95405.

Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer

New Hardware and Software Increases Accuracy For Targeting Malignant Cells, Sparing Healthy Tissue

SonaCare Medical, LLC, the makers of innovative High Intensity Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced the roll-out of its newest technology – called Sonafuse Profuse – introduced this summer at the treatment center in Puerto Vallarta, Mexico.

The Sonablate®  technology currently in use at the San Javier Marina Hospital has been updated with powerful new hardware components and the latest generation “3G” software including image fusion. Puerto Vallarta is now one of only three international treatment sites in the Americas offering image fusion and the newest software offering the benefits of multi-mode imaging that sees the outside and inside of the targeted area at the same time.

“Until now, Magnetic Resonance Images (MRI) had to be viewed separately from live HIFU images by doctors performing the procedure,” according to Dr. Michael Lazar, a leading urologist and pioneer of HIFU who has been treating prostate cancer patients in Puerto Vallarta since 2007. “Now using advanced software, both image sets are combined enabling us to gain an even clearer picture of cancer cells and their precise location so they can be more accurately, and individually, targeted using ultrasound energy.”

Sonafuse Profuse technology fuses a previously obtained magnetic resonance image (MRI) with live ultrasound during the HIFU procedure. This allows the visualization of regions of abnormality visible with MRI, but not normally visible with ultrasound during the procedure for targeted treatment. The fusion program is based on Artemis Profuse software from Eigen, one of three SonaCare Medical fusion partners that provide seamless integration with physicians’ targeted biopsy systems.

Dr. Lazar said there are many benefits associated with advanced HIFU therapy, including sound-based, tissue sparing, non-surgical intervention for the treatment of prostate cancer and more favorable outcomes for patients.

He said modern imaging technology is changing today’s urological cancer landscape, enabling doctors to increase their detection of genitourinary cancer as well as better tumor and cancer cell visualization, especially among smaller confined tumors. He said it is also helping physicians achieve better, targeted biopsies and helps in the diagnosis of prostate cancer among younger patients.

HIFU is also being used in conjunction with CT scans to detect small, incidentally discovered, kidney renal masses – as well as for mpMRI prostate scans to identify specific regions of interest for targeted biopsy and ablation therapy.

For more information contact Dr. Michael Lazar, visit the California HIFU website, or call (707) 546-5553. Dr. Lazar’s office is located at 1140 Sonoma Ave #1A, Santa Rosa, CA 95405.

Active Ft. Bragg resident believes that “HIFU’s time has come”

Lazar HIFU testimonial 8.18

During annual checkups, Dennis Tavares’ primary doctor noticed two successive PSA increases and referred him to Urologist Dr. Michael Lazar. A sonic scan showed a series of dark spots. His prostate was getting bigger and was losing its shape and smoothness. Dr. Lazar performed a biopsy. Cancer cells were small, so there was little threat that they had spread. “My choices included getting a full or a partial prostate treatment. I chose to have only a partial oblation, with Dr. Lazar's concurrence, since the area with cancer was limited to only a section of the prostate. I got an MRI in Santa Rosa, had passports and was ready to go. We flew to Puerto Vallarta. The HIFU procedure was performed in a first-class medical center – very clean, neat and well furnished and everyone spoke English and very supportive. Dr. Lazar explained that I would be given spinal anesthesia so I would not move during the less than three-hour procedure. The next thing I knew I was waking up and just as Dr. Lazar predicted, with HIFU there was no bleeding and little to no chance of infection.”

 

By | August 18th, 2015|Dr. Michael Lazar, HIFU, Testimonials|0 Comments

Patient Testimonial: “I cannot be more appreciative of his comprehensive approach to treating patients ….” – Charles Lawrence

Click to View PDFAs a retired malpractice insurance professional, Charles Lawrence is very familiar with the many complex problems in today’s healthcare industry. He knows what to look for in a good doctor, and he deeply appreciates quality healthcare services. When Charles thought he was having urinary problems, he came to see Dr. Michael J. Lazar in Santa Rosa for an examination. Dr. Lazar didn’t find any problems with Charles’ urinary system, and Charles’ symptoms went away on their own shortly thereafter. However, Dr. Lazar discovered a lump on his thyroid that other physicians had failed to find previously …

Lazar testimonial 8.18 lower half

 

By | August 18th, 2015|Dr. Michael Lazar, Testimonials|0 Comments

Dr. Michael Lazar Named Medical Director of the SonaCare HIFU Pilot Project in Puerto Vallarta

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU, a medical procedure that applies high-intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue with prostate cancer through ablation. Dr. Lazar is working closely with SonaCare to bring this innovative service to Americans with this disease. Leading Santa Rosa, California, Urologist Dr. Michael Lazar, has been named Medical Director of the High Intensity Focused Ultrasound (HIFU) project currently underway at a well-equipped medical facility in Puerto Valarta, Mexico. This procedure involves the implementation of a new technology using sound waves to destroy cancer cells in the male prostate gland.

This project is sponsored by SonaCare Medical, LLC, developers of minimally-invasive HIFU technologies designed to significantly improve the quality of life for prostate cancer patients using focused ultrasound energy waves emitted from the firm’s Sonablate® 500 transrectal probe to destroy cancer cells without conventional surgery.

SonaCare’s Sonablate® 500HIFU Ablation Software™ utilizing T3 Technology™ enables the operator to target ablation zones with sophisticated planning and localization tools, treat disease with pin point accuracy while sparing untargeted tissue and track with advanced real-time ultrasound imaging.

Dr. Lazar has been a pioneer in the application of HIFU by working closely with SonaCare physicians and engineers in the development of this new technique. He has been treating patients with successful HIFU procedures with minimal side effects since April 2007.

“In the past, the entire prostate gland was removed surgically or irradiated causing issues associated with incontinence, erectile dysfunction (ED) and weeks of recovery,” says Dr. Lazar. “Today we can cure the cancer by treating the whole gland, or focally in the region of the cancer only, in just a few hours without blood loss and minimal side effects. This is a real game changer. Virtually all patients can be up and walking out of the hospital the same day to resume normal activities with little or no pain.”

Dr. Lazar said that cancer can now be detected in very early stages based on PSA blood testing along with MRI and ultrasound scans and a biopsy. This may allow treating only the areas with cancer cells using HIFU rather than excising the whole gland with a scalpel. Another factor to consider is that many cancers of the prostate progress slowly, so there is less reason to destroy the entire prostate just to address localized cancer that has not spread throughout the gland, a significant factor when it comes to maintaining erectile function and urine flow through the urethra following a full oblation (removal) procedure.

While HIFU is pending FDA approval for general use in the United States, SonaCare Medical is currently conducting a clinical trial in the U.S. and Canada to determine the safety and efficacy of a minimally invasive prostate cancer treatment using HIFU with the Sonablate® 500. The trial is for patients who have recurrent prostate cancer after receiving a previous treatment with external beam radiation therapy. To be eligible to be considered for the U.S. recurrent trials, candidates must:

• Have been treated with external beam radiation therapy two or more years prior;
• Have low-risk, organ-confined recurrent prostate cancer T1c or T2a;
• Be between the ages of 40 and 85;
• Have a PSA level between 0.5ng/mL and 10ng/mL;
• Have a recent (within six months) prostate biopsy that is positive for cancer.

There is no cost to enroll in the study, nor does it require health insurance. For more information call 877.605.HIFU.

For more information about Dr. Michael Lazar visit this page, or call (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, Santa Rosa, CA 95405.

By | July 23rd, 2015|Dr. Michael Lazar, HIFU, News, Prostate Cancer|0 Comments